{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T17:01:18Z","timestamp":1791478878858,"version":"4.3.4"},"reference-count":117,"publisher":"MDPI AG","issue":"1","license":[{"start":{"date-parts":[[2021,1,2]],"date-time":"2021-01-02T00:00:00Z","timestamp":1609545600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>Mastocytosis is a rare and complex disease characterized by expansion of clonal mast cells (MC) in skin and\/or various internal organ systems. Involvement of internal organs leads to the diagnosis of systemic mastocytosis (SM). The WHO classification divides SM into indolent SM, smoldering SM and advanced SM variants, including SM with an associated hematologic neoplasm, aggressive SM, and MC leukemia. Historically, genetic analysis of individuals with pure cutaneous mastocytosis (CM) and SM have focused primarily on cohort studies of inherited single nucleotide variants and acquired pathogenic variants. The most prevalent pathogenic variant (mutation) in patients with SM is KIT p.D816V, which is detectable in most adult patients. Other somatic mutations have also been identified\u2014especially in advanced SM\u2014in TET2, SRSF2, ASXL1, RUNX1, CBL and JAK2, and shown to impact clinical and cellular phenotypes. Although only small patient cohorts have been analyzed, disease associations have also been identified in several germline variants within genes encoding certain cytokines or their receptors (IL13, IL6, IL6R, IL31, IL4R) and toll-like receptors. More recently, an increased prevalence of hereditary alpha-tryptasemia (H\u03b1T) caused by increased TPSAB1 copy number encoding alpha-tryptase has been described in patients with SM. Whereas H\u03b1T is found in 3\u20136% of general Western populations, it is identified in up to 17% of patients with SM. In the current manuscript we review the prevalence, functional role and clinical impact of various germline and somatic genetic variants in patients with mastocytosis.<\/jats:p>","DOI":"10.3390\/ijms22010411","type":"journal-article","created":{"date-parts":[[2021,1,3]],"date-time":"2021-01-03T19:54:46Z","timestamp":1609703686000},"page":"411","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":34,"title":["Clinical Impact of Inherited and Acquired Genetic Variants in Mastocytosis"],"prefix":"10.3390","volume":"22","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6286-0693","authenticated-orcid":false,"given":"Boguslaw","family":"Nedoszytko","sequence":"first","affiliation":[{"name":"Department of Dermatology, Allergology and Venereology, Medical University of Gdansk, 80-211 Gdansk, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3990-4408","authenticated-orcid":false,"given":"Michel","family":"Arock","sequence":"additional","affiliation":[{"name":"Department of Hematology, APHP, H\u00f4pital Piti\u00e9-Salp\u00eatri\u00e8re and Sorbonne University, 75013 Paris, France"},{"name":"Centre de Recherche des Cordeliers, INSERM, Sorbonne Universit\u00e9, Universit\u00e9 de Paris, Cell Death and Drug Resistance in Hematological Disorders Team, 75006 Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan","family":"Lyons","sequence":"additional","affiliation":[{"name":"Laboratory of Allergic Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892-188, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4175-4816","authenticated-orcid":false,"given":"Guillaume","family":"Bachelot","sequence":"additional","affiliation":[{"name":"Department of Hematology, APHP, H\u00f4pital Piti\u00e9-Salp\u00eatri\u00e8re and Sorbonne University, 75013 Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lawrence","family":"Schwartz","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Division of Rheumatology, Allergy &amp; Immunology, Virginia Commonwealth University, Richmond, VA 23298, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Reiter","sequence":"additional","affiliation":[{"name":"University Hospital Mannheim, Heidelberg University, 68167 Mannheim, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9148-9398","authenticated-orcid":false,"given":"Mohamad","family":"Jawhar","sequence":"additional","affiliation":[{"name":"University Hospital Mannheim, Heidelberg University, 68167 Mannheim, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9208-5264","authenticated-orcid":false,"given":"Juliana","family":"Schwaab","sequence":"additional","affiliation":[{"name":"University Hospital Mannheim, Heidelberg University, 68167 Mannheim, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Magdalena","family":"Lange","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Allergology and Venereology, Medical University of Gdansk, 80-211 Gdansk, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0917-4117","authenticated-orcid":false,"given":"Georg","family":"Greiner","sequence":"additional","affiliation":[{"name":"Department of Laboratory Medicine, Medical University of Vienna, 1090 Vienna, Austria"},{"name":"Ludwig Boltzmann Institute for Hematology and Oncology, Medical University of Vienna, 1090 Vienna, Austria"},{"name":"Ihr Labor, Medical Diagnostic Laboratories, 1220 Vienna, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7374-4380","authenticated-orcid":false,"given":"Gregor","family":"Hoermann","sequence":"additional","affiliation":[{"name":"Ludwig Boltzmann Institute for Hematology and Oncology, Medical University of Vienna, 1090 Vienna, Austria"},{"name":"MLL Munich Leukemia Laboratory, 81377 Munich, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marek","family":"Niedoszytko","sequence":"additional","affiliation":[{"name":"Department of Allergology, Medical University of Gdansk, 80-211 Gdansk, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7781-8260","authenticated-orcid":false,"given":"Dean","family":"Metcalfe","sequence":"additional","affiliation":[{"name":"Laboratory of Allergic Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892-188, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0456-5095","authenticated-orcid":false,"given":"Peter","family":"Valent","sequence":"additional","affiliation":[{"name":"Ludwig Boltzmann Institute for Hematology and Oncology, Medical University of Vienna, 1090 Vienna, Austria"},{"name":"Department of Internal Medicine I, Division of Hematology and Hemostaseology, Medical University of Vienna, 1090 Vienna, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2021,1,2]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"2954","DOI":"10.1182\/blood.V84.9.2954.2954","article-title":"Origin of human mast cells: Development from transplanted hematopoietic stem cells after allogeneic bone marrow transplantation","volume":"84","author":"Fritsch","year":"1994","journal-title":"Blood"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"2673","DOI":"10.1038\/s41375-019-0460-6","article-title":"Identification of a leukemia-initiating stem cell in human mast cell leukemia","volume":"33","author":"Eisenwort","year":"2019","journal-title":"Leukemia"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"2460","DOI":"10.1182\/blood-2013-04-496448","article-title":"Comprehensive mutational profiling in advanced systemic mastocytosis","volume":"122","author":"Schwaab","year":"2013","journal-title":"Blood"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1038\/leu.2015.4","article-title":"Molecular profiling of myeloid progenitor cells in multi-mutated advanced systemic mastocytosis identifies KIT D816V as a distinct and late event","volume":"29","author":"Jawhar","year":"2015","journal-title":"Leukemia"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"106404","DOI":"10.1016\/j.leukres.2020.106404","article-title":"Evolution of clonal dynamics and differential response to targeted therapy in a case of systemic mastocytosis with associated myelodysplastic syndrome","volume":"95","author":"Yun","year":"2020","journal-title":"Leuk. Res."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1016\/S0145-2126(01)00038-8","article-title":"Diagnostic criteria and classification of mastocytosis: A consensus proposal","volume":"25","author":"Valent","year":"2001","journal-title":"Leuk. Res."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.jaci.2004.02.045","article-title":"Diagnosis and classification of mast cell proliferative disorders: Delineation from immunologic diseases and non\u2013mast cell hematopoietic neoplasms","volume":"114","author":"Valent","year":"2004","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1111\/j.1365-2362.2007.01807.x","article-title":"Standards and standardization in mastocytosis: Consensus Statements on Diagnostics, Treatment Recommendations and Response Criteria","volume":"37","author":"Valent","year":"2007","journal-title":"Eur. J. Clin. Investig."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1159\/000101711","article-title":"Mastocytosis: State of the Art","volume":"74","author":"Horny","year":"2007","journal-title":"Pathobiology"},{"key":"ref_10","first-page":"62","article-title":"Mastocytosis","volume":"Volume 3","author":"Swerdlow","year":"2017","journal-title":"WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1420","DOI":"10.1182\/blood-2016-09-731893","article-title":"Mastocytosis: 2016 updated WHO classification and novel emerging treatment concepts","volume":"129","author":"Valent","year":"2017","journal-title":"Blood"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1182\/blood-2012-07-442400","article-title":"Mast cell leukemia","volume":"121","author":"Lhermitte","year":"2013","journal-title":"Blood"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.3324\/haematol.2016.146563","article-title":"Advanced systemic mastocytosis: From molecular and genetic progress to clinical practice","volume":"101","author":"Ustun","year":"2016","journal-title":"Haematologica"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1038\/leu.2015.24","article-title":"KIT mutation analysis in mast cell neoplasms: Recommendations of the European Competence Network on Mastocytosis","volume":"29","author":"Arock","year":"2015","journal-title":"Leukemia"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"2366","DOI":"10.1182\/blood-2006-04-015545","article-title":"KIT mutation in mast cells and other bone marrow hematopoietic cell lineages in systemic mast cell disorders: A prospective study of the Spanish Network on Mastocytosis (REMA) in a series of 113 patients","volume":"108","author":"Montero","year":"2006","journal-title":"Blood"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1182\/blood.2018886507","article-title":"Frequency and prognostic impact of KIT and other genetic variants in indolent systemic mastocytosis","volume":"134","author":"Henriques","year":"2019","journal-title":"Blood"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1038\/leu.2011.293","article-title":"An immature immunophenotype of bone marrow mast cells predicts for multilineage D816V KIT mutation in systemic mastocytosis","volume":"26","author":"Teodosio","year":"2011","journal-title":"Leukemia"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1111\/j.1600-0609.2012.01789.x","article-title":"Circulating KITD816V mutation-positive non-mast cells in peripheral blood are characteristic of indolent systemic mastocytosis","volume":"89","author":"Kristensen","year":"2012","journal-title":"Eur. J. Haematol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.jaci.2015.08.034","article-title":"Cutaneous manifestations in patients with mastocytosis: Consensus report of the European Competence Network on Mastocytosis; the American Academy of Allergy, Asthma & Immunology; and the European Academy of Allergology and Clinical Immunology","volume":"137","author":"Hartmann","year":"2016","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/j.iac.2018.04.001","article-title":"Cutaneous Mastocytosis in Adults and Children","volume":"38","author":"Matito","year":"2018","journal-title":"Immunol. Allergy Clin. N. Am."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"533","DOI":"10.5114\/aoms.2012.29534","article-title":"Mastocytosis in children and adults: Clinical disease heterogeneity","volume":"8","author":"Lange","year":"2012","journal-title":"Arch. Med. Sci."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1111\/j.1468-3083.2011.04365.x","article-title":"Clinical aspects of paediatric mastocytosis: A review of 101 cases","volume":"27","author":"Lange","year":"2011","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1159\/000328760","article-title":"Definitions, Criteria and Global Classification of Mast Cell Disorders with Special Reference to Mast Cell Activation Syndromes: A Consensus Proposal","volume":"157","author":"Valent","year":"2011","journal-title":"Int. Arch. Allergy Immunol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1111\/all.12126","article-title":"Mast cell activation syndromes: Definition and classification","volume":"68","author":"Valent","year":"2013","journal-title":"Allergy"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1016\/j.jaip.2019.01.006","article-title":"Proposed Diagnostic Algorithm for Patients with Suspected Mast Cell Activation Syndrome","volume":"7","author":"Valent","year":"2019","journal-title":"J. Allergy Clin. Immunol. Pract."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1182\/blood.V98.3.880","article-title":"Association of the Q576R polymorphism in the interleukin-4 receptor \u03b1 chain with indolent mastocytosis limited to the skin","volume":"98","author":"Daley","year":"2001","journal-title":"Blood"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1111\/j.1398-9995.2008.01827.x","article-title":"Interleukin-13promoter gene polymorphism -1112C\/T is associated with the systemic form of mastocytosis","volume":"64","author":"Nedoszytko","year":"2009","journal-title":"Allergy"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"47","DOI":"10.2340\/00015555-2474","article-title":"Interleukin-31 Polymorphisms and Serum IL-31 Level in Patients with Mastocytosis: Correlation with Clinical Presen-tation and Pruritus","volume":"97","author":"Lange","year":"2017","journal-title":"Acta Derm. Venereol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1111\/bjh.12086","article-title":"Comparative analysis of IL6 and IL6 receptor gene polymorphisms in mastocytosis","volume":"160","author":"Rausz","year":"2013","journal-title":"Br. J. Haematol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1159\/000489343","article-title":"The Possible Role of Gene Variant Coding Nonfunctional Toll-Like Receptor 2 in the Pathogenesis of Mastocytosis","volume":"177","author":"Nedoszytko","year":"2018","journal-title":"Int. Arch. Allergy Immunol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1126\/science.1221064","article-title":"New Paradigms in Type 2 Immunity","volume":"337","author":"Pulendran","year":"2012","journal-title":"Science"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1556\/030.62.2015.4.2","article-title":"Interleukin-13 as an important cytokine: A review on its roles in some human diseases","volume":"62","author":"Seyfizadeh","year":"2015","journal-title":"Acta Microbiol. Immunol. Hung."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/j.cell.2007.12.030","article-title":"Molecular and Structural Basis of Cytokine Receptor Pleiotropy in the Interleukin-4\/13 System","volume":"132","author":"Laporte","year":"2008","journal-title":"Cell"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1111\/j.1398-9995.2006.01139.x","article-title":"Mast cells express IL-13R alpha 1: IL-13 promotes human lung mast cell proliferation and Fc epsilon RI expression","volume":"61","author":"Kaur","year":"2006","journal-title":"Allergy"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.cyto.2015.05.019","article-title":"Mast cell production and response to IL-4 and IL-13","volume":"75","author":"McLeod","year":"2015","journal-title":"Cytokine"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/S0091-6749(98)70140-X","article-title":"Human mast cells produce IL-13 by high-affinity IgE receptor cross-linking: Enhanced IL-13 production by IL-4\u2013primed human mast cells","volume":"102","author":"Toru","year":"1998","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1111\/j.1365-2222.2011.03953.x","article-title":"Current concepts of IgE regulation and impact of genetic determinants","volume":"42","author":"Potaczek","year":"2012","journal-title":"Clin. Exp. Allergy"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1016\/j.ejcb.2011.07.006","article-title":"Signaling by IL-31 and functional consequences","volume":"91","author":"Cornelissen","year":"2012","journal-title":"Eur. J. Cell Biol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s11882-014-0423-y","article-title":"Interleukin-31: A Novel Diagnostic Marker of Allergic Diseases","volume":"14","author":"Rabenhorst","year":"2014","journal-title":"Curr. Allergy Asthma Rep."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1016\/j.jaci.2005.10.046","article-title":"IL-31 is associated with cutaneous lymphocyte antigen\u2013positive skin homing T cells in patients with atopic dermatitis","volume":"117","author":"Bilsborough","year":"2006","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"5942","DOI":"10.1182\/blood-2008-09-179416","article-title":"Pivotal role of mast cells in pruritogenesis in patients with myeloproliferative disorders","volume":"113","author":"Ishii","year":"2009","journal-title":"Blood"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"3526","DOI":"10.4049\/jimmunol.0900712","article-title":"Antimicrobial Peptides Human \u03b2-Defensins and Cathelicidin LL-37 Induce the Secretion of a Pruritogenic Cytokine IL-31 by Human Mast Cells","volume":"184","author":"Niyonsaba","year":"2010","journal-title":"J. Immunol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1016\/j.jaci.2008.05.047","article-title":"Correlation of IL-31 serum levels with severity of atopic dermatitis","volume":"122","author":"Raap","year":"2008","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1016\/j.jaci.2012.11.008","article-title":"Serum IL-31 levels are increased in a subset of patients with mastocytosis and correlate with disease severity in adult patients","volume":"132","author":"Hartmann","year":"2013","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1016\/j.jaci.2007.07.065","article-title":"A common haplotype of the IL-31 gene influencing gene expression is associated with nonatopic eczema","volume":"120","author":"Schulz","year":"2007","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1111\/j.1468-3083.2012.04649.x","article-title":"Association of distinct IL-31 polymorphisms with pruritus and severity of atopic dermatitis","volume":"27","author":"Sikorska","year":"2013","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_47","first-page":"62","article-title":"The frequencies of haplotypes defined by three polymorphisms of theIL-31gene: \u22121066, \u22122057, and IVS2+12 in Polish patients with atopic dermatitis","volume":"54","author":"Trzeciak","year":"2014","journal-title":"Int. J. Dermatol."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1067\/mai.2002.120524","article-title":"Levels of mast-cell growth factors in plasma and in suction skin blister fluid in adults with mastocytosis: Correlation with dermal mast-cell numbers and mast-cell tryptase","volume":"109","author":"Brockow","year":"2002","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/j.clim.2005.01.011","article-title":"IL-6 levels predict disease variant and extent of organ involvement in patients with mastocytosis","volume":"115","author":"Brockow","year":"2005","journal-title":"Clin. Immunol."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1038\/leu.2015.176","article-title":"Increased IL6 plasma levels in indolent systemic mastocytosis patients are associated with high risk of disease progression","volume":"30","author":"Mayado","year":"2016","journal-title":"Leukemia"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1159\/000063858","article-title":"Serum interleukin-6 reflects disease severity and osteoporosis in mastocytosis patients","volume":"128","author":"Theoharides","year":"2002","journal-title":"Int. Arch. Allergy Immunol."},{"key":"ref_52","first-page":"238","article-title":"Serum tryptase, interleukin 6 and SCORMA Index as disease severity parameters in childhood mastocytosis","volume":"27","author":"Lange","year":"2010","journal-title":"Post\u0119py Dermatol. Alergol."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"124","DOI":"10.3324\/haematol.2018.212126","article-title":"Oncogenic D816V-KIT signaling in mast cells causes persistent IL-6 production","volume":"105","author":"Bandara","year":"2020","journal-title":"Haematologica"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"5","DOI":"10.3324\/haematol.2019.234864","article-title":"KIT D816V and the cytokine storm in mastocytosis: Production and role of interleukin-6","volume":"105","author":"Valent","year":"2020","journal-title":"Haematologica"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"185","DOI":"10.3389\/fimmu.2012.00185","article-title":"TLR signaling in mast cells: Common and unique features","volume":"3","author":"Sandig","year":"2012","journal-title":"Front. Immunol."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1016\/j.jaci.2018.01.034","article-title":"Mast cells signal their importance in health and disease","volume":"142","author":"Olivera","year":"2018","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_57","first-page":"968","article-title":"Toll-like receptor 2-mediated MAPKs and NF-\u03baB activation requires the GNAO1- dependent pathway in human mast cells","volume":"12","author":"Lin","year":"2016","journal-title":"Integr. Biol."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1177\/03946320110240S408","article-title":"TLR2 and TLR4 gene polymorphisms and atopic dermatitis in Italian children: A multicenter study","volume":"24","author":"Salpietro","year":"2011","journal-title":"Int. J. Immunopathol. Pharmacol."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1111\/j.1398-9995.2008.01721.x","article-title":"Dysregulation of toll-like receptor-2 (TLR-2)-induced effects in monocytes from patients with atopic dermatitis: Impact of the TLR-2 R753Q polymorphism","volume":"63","author":"Niebuhr","year":"2008","journal-title":"Allergy"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1016\/j.jaci.2007.11.029","article-title":"The Toll-like receptor 2 R753Q mutation modifies cytokine production and Toll-like receptor expression in atopic dermatitis","volume":"121","author":"Dalpke","year":"2008","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_61","first-page":"85","article-title":"The significance of Toll-like receptor (TLR) 2 and 9 gene polymorphisms in psoriasis","volume":"34","author":"Sobjanek","year":"2017","journal-title":"Adv. Dermatol. Allergol."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"1162","DOI":"10.1016\/j.jaci.2003.07.008","article-title":"Gene expression analysis in mastocytosis reveals a highly consistent profile with candidate molecular markers","volume":"112","author":"Akin","year":"2003","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1016\/j.jaci.2012.12.674","article-title":"Gene expression profile of highly purified bone marrow mast cells in systemic mastocytosis","volume":"131","author":"Teodosio","year":"2013","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1111\/j.1398-9995.2010.02477.x","article-title":"Gene expression profile, pathways, and transcriptional system regulation in indolent systemic mastocytosis","volume":"66","author":"Niedoszytko","year":"2010","journal-title":"Allergy"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1111\/j.1398-9995.2010.02521.x","article-title":"Gene expression analysis predicts insect venom anaphylaxis in indolent systemic mastocytosis","volume":"66","author":"Niedoszytko","year":"2010","journal-title":"Allergy"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1007\/s00005-016-0397-7","article-title":"The Role of TRAF4 and B3GAT1 Gene Expression in the Food Hypersensitivity and Insect Venom Allergy in Mastocytosis","volume":"64","author":"Niedoszytko","year":"2016","journal-title":"Arch. Immunol. Ther. Exp."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1016\/j.it.2017.01.008","article-title":"Positive and Negative Signals in Mast Cell Activation","volume":"38","author":"Nilsson","year":"2017","journal-title":"Trends Immunol."},{"key":"ref_68","first-page":"237","article-title":"Identification of a mast-cell-specific receptor crucial for pseudo-allergic drug reactions","volume":"519","author":"McNeil","year":"2015","journal-title":"Nat. Cell Biol."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1016\/j.jaci.2016.04.051","article-title":"Roles of Mas-related G protein-coupled receptor X2 on mast cell-mediated host defense, pseudoallergic drug reactions, and chronic inflammatory diseases","volume":"138","author":"Subramanian","year":"2016","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"1322","DOI":"10.1016\/j.bbrc.2006.08.177","article-title":"Immunoglobulin E-independent activation of mast cell is mediated by Mrg receptors","volume":"349","author":"Tatemoto","year":"2006","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"343","DOI":"10.4049\/jimmunol.1701793","article-title":"Naturally Occurring Missense MRGPRX2 Variants Display Loss of Function Phenotype for Mast Cell Degranulation in Response to Substance P, Hemokinin-1, Human \u03b2-Defensin-3, and Icatibant","volume":"201","author":"Alkanfari","year":"2018","journal-title":"J. Immunol."},{"key":"ref_72","doi-asserted-by":"crossref","unstructured":"Na Ayudhya, C.C., Roy, S., Alkanfari, I., Ganguly, A., and Ali, H. (2019). Identification of Gain and Loss of Function Missense Variants in MRGPRX2\u2019s Transmembrane and Intracellular Domains for Mast Cell Activation by Substance P. Int. J. Mol. Sci., 20.","DOI":"10.3390\/ijms20215247"},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"e12655","DOI":"10.1111\/sji.12655","article-title":"Endogenous protein and enzyme fragments induce immunoglobulin E-independent activation of mast cells via a G protein-coupled receptor, MRGPRX2","volume":"87","author":"Tatemoto","year":"2018","journal-title":"Scand. J. Immunol."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"2089","DOI":"10.1016\/j.jaip.2019.01.059","article-title":"Anaphylaxis to quinolones in mastocytosis: Hypothesis on the mechanism","volume":"7","author":"Garro","year":"2019","journal-title":"J. Allergy Clin. Immunol. Pract."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"2091","DOI":"10.1016\/j.jaip.2019.02.015","article-title":"Mastocytosis, Quinolones, MRGPRX2, and Anaphylaxis","volume":"7","author":"Weiler","year":"2019","journal-title":"J. Allergy Clin. Immunol. Pract."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1056\/NEJMoa1500611","article-title":"Vibratory Urticaria Associated with a Missense Variant in ADGRE2","volume":"374","author":"Boyden","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1056\/NEJMoa1102140","article-title":"Cold Urticaria, Immunodeficiency, and Autoimmunity Related toPLCG2Deletions","volume":"366","author":"Ombrello","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1016\/j.jaci.2009.09.035","article-title":"Familial atypical cold urticaria: Description of a new hereditary disease","volume":"124","author":"Gandhi","year":"2009","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1001\/jamadermatol.2014.5641","article-title":"Distinct Cutaneous Manifestations and Cold-Induced Leukocyte Activation Associated With PLCG2 Mutations","volume":"151","author":"Aderibigbe","year":"2015","journal-title":"JAMA Dermatol."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"1471","DOI":"10.1016\/j.jaci.2013.11.039","article-title":"Mendelian inheritance of elevated serum tryptase associated with atopy and connective tissue abnormalities","volume":"133","author":"Lyons","year":"2014","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"1564","DOI":"10.1038\/ng.3696","article-title":"Elevated basal serum tryptase identifies a multisystem disorder associated with increased TPSAB1 copy number","volume":"48","author":"Lyons","year":"2016","journal-title":"Nat. Genet."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1016\/j.iac.2018.04.003","article-title":"Hereditary Alpha Tryptasemia: Genotyping and Associated Clinical Features","volume":"38","author":"Lyons","year":"2018","journal-title":"Immunol. Allergy Clin. N. Am."},{"key":"ref_83","doi-asserted-by":"crossref","unstructured":"Greiner, G., Sprinzl, B., G\u00f3rska, A., Ratzinger, F., Gurbisz, M., Witzeneder, N., Schmetterer, K.G., Gisslinger, B., Uyanik, G., and Hadzijusufovic, E. (2020). Hereditary alpha tryptasemia is a valid genetic biomarker for severe mediator-related symptoms in mastocytosis. Blood.","DOI":"10.1182\/blood.2020006157"},{"key":"ref_84","doi-asserted-by":"crossref","unstructured":"Lyons, J.J., Chovanec, J., O\u2019Connell, M.P., Liu, Y., \u0160elb, J., Zanotti, R., Bai, Y., Kim, J., DiMaggio, T., and Schwartz, L.B. (2020). Heritable risk for severe anaphylaxis associated with increased \u03b1-tryptase-encoding germline copy number at TPSAB1. J. Allergy Clin. Immunol.","DOI":"10.1016\/j.jaci.2020.06.035"},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"3549","DOI":"10.1016\/j.jaip.2020.05.057","article-title":"Hereditary Alpha-Tryptasemia: UK Prevalence and Variability in Disease Expression","volume":"8","author":"Robey","year":"2020","journal-title":"J. Allergy Clin. Immunol. Pract."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"2348","DOI":"10.1084\/jem.20190701","article-title":"Impact of naturally forming human alpha\/beta-tryptase heterotetramers in the pathogenesis of hereditary alpha-tryptasemia","volume":"216","author":"Le","year":"2019","journal-title":"J. Exp. Med."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1007\/s10875-018-0506-y","article-title":"First Identification of an Inherited TPSAB1 Quintuplication in a Patient with Clonal Mast Cell Disease","volume":"38","author":"Sabato","year":"2018","journal-title":"J. Clin. Immunol."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"1619","DOI":"10.1152\/physrev.00046.2011","article-title":"Stem Cell Factor Receptor\/c-Kit: From Basic Science to Clinical Implications","volume":"92","author":"Lennartsson","year":"2012","journal-title":"Physiol. Rev."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/j.iac.2014.01.002","article-title":"Functional deregulation of KIT: Link to mast cell proliferative diseases and other neoplasms","volume":"34","author":"Cruse","year":"2014","journal-title":"Immunol. Allergy Clin. N. Am."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1038\/jid.2009.281","article-title":"Pediatric Mastocytosis Is a Clonal Disease Associated with D816V and Other Activating c-KIT Mutations","volume":"130","author":"Bodemer","year":"2010","journal-title":"J. Investig. Dermatol."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1111\/j.1365-2141.2007.06619.x","article-title":"Recent advances in the understanding of mastocytosis: The role of KIT mutations","volume":"138","author":"Orfao","year":"2007","journal-title":"Br. J. Haematol."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/j.iac.2014.01.009","article-title":"Molecular defects in mastocytosis: KIT and beyond KIT","volume":"34","author":"Bibi","year":"2014","journal-title":"Immunol. Allergy Clin. N. Am."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1016\/j.jaci.2015.05.008","article-title":"Clinical, immunophenotypic, and molecular characteristics of well-differentiated systemic mastocytosis","volume":"137","author":"Morgado","year":"2016","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/j.ebiom.2019.03.089","article-title":"Single-cell analysis reveals the KIT D816V mutation in haematopoietic stem and progenitor cells in systemic mastocytosis","volume":"43","author":"Grootens","year":"2019","journal-title":"EBioMedicine"},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"1146","DOI":"10.1002\/ajh.24553","article-title":"Systemic mastocytosis in adults: 2017 update on diagnosis, risk stratification and management","volume":"91","author":"Pardanani","year":"2016","journal-title":"Am. J. Hematol."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1111\/bjh.13560","article-title":"Concurrent activating KIT mutations in systemic mastocytosis","volume":"173","author":"Lasho","year":"2016","journal-title":"Br. J. Haematol."},{"key":"ref_97","doi-asserted-by":"crossref","unstructured":"de Beauchene, I.C., Allain, A., Panel, N., Laine, E., Trouve, A., Dubreuil, P., and Tchertanov, L. (2014). Hotspot mutations in KIT receptor differentially modulate its allosterically coupled conformational dynamics: Impact on activation and drug sensitivity. PLoS Comput. Biol., 10.","DOI":"10.1371\/journal.pcbi.1003749"},{"key":"ref_98","doi-asserted-by":"crossref","unstructured":"Laine, E., de Beauchene, I.C., Perahia, D., Auclair, C., and Tchertanov, L. (2011). Mutation D816V alters the internal structure and dynamics of c-KIT receptor cytoplasmic region: Implications for dimerization and activation mechanisms. PLoS Comput. Biol., 7.","DOI":"10.1371\/journal.pcbi.1002068"},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"14665","DOI":"10.1073\/pnas.93.25.14665","article-title":"Oncogenic mutation in the Kit receptor tyrosine kinase alters substrate specificity and induces degradation of the protein tyrosine phosphatase SHP-1","volume":"93","author":"Piao","year":"1996","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"417","DOI":"10.3324\/haematol.2013.098442","article-title":"Co-operating STAT5 and AKT signaling pathways in chronic myeloid leukemia and mastocytosis: Possible new targets of therapy","volume":"99","author":"Bibi","year":"2014","journal-title":"Haematologica"},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"2463","DOI":"10.1182\/blood-2007-09-115477","article-title":"Oncogenic Kit controls neoplastic mast cell growth through a Stat5\/PI3-kinase signaling cascade","volume":"112","author":"Harir","year":"2008","journal-title":"Blood"},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"2416","DOI":"10.2353\/ajpath.2009.080953","article-title":"Expression of activated STAT5 in neoplastic mast cells in systemic mastocytosis: Subcellular distribution and role of the transforming oncoprotein KIT D816V","volume":"175","author":"Baumgartner","year":"2009","journal-title":"Am. J. Pathol."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1038\/leu.2017.338","article-title":"Drug-induced inhibition of phosphorylation of STAT5 overrides drug resistance in neoplastic mast cells","volume":"32","author":"Peter","year":"2018","journal-title":"Leukemia"},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"2593","DOI":"10.1182\/blood-2007-02-076471","article-title":"The tyrosine kinase FES is an essential effector of KITD816V proliferation signal","volume":"110","author":"Voisset","year":"2007","journal-title":"Blood"},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"6803","DOI":"10.1182\/blood-2011-06-359984","article-title":"mTORC1 and mTORC2 differentially regulate homeostasis of neoplastic and non-neoplastic human mast cells","volume":"118","author":"Smrz","year":"2011","journal-title":"Blood"},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1182\/blood-2005-06-2433","article-title":"Rapamycin inhibits growth and survival of D816V-mutated c-kit mast cells","volume":"108","author":"Lepelletier","year":"2006","journal-title":"Blood"},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"1885","DOI":"10.1182\/blood-2010-06-289959","article-title":"KIT-D816V-independent oncogenic signaling in neoplastic cells in systemic mastocytosis: Role of Lyn and Btk activation and disruption by dasatinib and bosutinib","volume":"118","author":"Gleixner","year":"2011","journal-title":"Blood"},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"2344","DOI":"10.1016\/j.ajpath.2011.01.020","article-title":"Identification of oncostatin M as a STAT5-dependent mediator of bone marrow remodeling in KIT D816V-positive systemic mastocytosis","volume":"178","author":"Hoermann","year":"2011","journal-title":"Am. J. Pathol."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"3629","DOI":"10.1182\/blood-2010-07-293548","article-title":"KIT signaling regulates MITF expression through miRNAs in normal and malignant mast cell proliferation","volume":"117","author":"Lee","year":"2011","journal-title":"Blood"},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"3031","DOI":"10.1182\/blood-2006-07-032714","article-title":"Identification of MCL1 as a novel target in neoplastic mast cells in systemic mastocytosis: Inhibition of mast cell survival by MCL1 antisense oligonucleotides and synergism with PKC412","volume":"109","author":"Aichberger","year":"2007","journal-title":"Blood"},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1038\/leu.2015.284","article-title":"Additional mutations in SRSF2, ASXL1 and\/or RUNX1 identify ahigh-risk group of patients with KIT D816V+ advanced systemic mastocytosis","volume":"30","author":"Jawhar","year":"2016","journal-title":"Leukemia"},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"2342","DOI":"10.1038\/leu.2016.190","article-title":"Splenomegaly, elevated alkaline phosphatase and mutations in the SRSF2\/ASXL1\/RUNX1 gene panel are strong adverse prognostic markers in patients with systemic mastocytosis","volume":"30","author":"Jawhar","year":"2016","journal-title":"Leukemia"},{"key":"ref_113","doi-asserted-by":"crossref","unstructured":"Damaj, M.J.G., Chandesris, O., Hanssens, K., Soucie, E., Canioni, D., Kolb, B., Durieu, I., Gyan, E., Livideanu, C., and Ch\u00e8ze, S. (2014). ASXL1 but not TET2 mutations adversely impact overall survival of patients suffering systemic mastocytosis with associated clonal hematologic non-mast-cell diseases. PLoS ONE, 9.","DOI":"10.1371\/journal.pone.0085362"},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1111\/bjh.13865","article-title":"ASXL1 and CBL mutations are independently predictive of inferior survival in advanced systemic mastocytosis","volume":"175","author":"Pardanani","year":"2015","journal-title":"Br. J. Haematol."},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"2846","DOI":"10.1200\/JCO.19.00640","article-title":"MARS: Mutation-Adjusted Risk Score for Advanced Systemic Mastocytosis","volume":"37","author":"Jawhar","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"2814","DOI":"10.1182\/bloodadvances.2018020628","article-title":"Impact of somatic and germline mutations on the outcome of systemic mastocytosis","volume":"2","author":"Merker","year":"2018","journal-title":"Blood Adv."},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"2964","DOI":"10.1182\/bloodadvances.2018026245","article-title":"Mayo alliance prognostic system for mastocytosis: Clinical and hybrid clinical-molecular models","volume":"2","author":"Pardanani","year":"2018","journal-title":"Blood Adv."}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/22\/1\/411\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T05:06:23Z","timestamp":1760159183000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/22\/1\/411"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1,2]]},"references-count":117,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2021,1]]}},"alternative-id":["ijms22010411"],"URL":"https:\/\/doi.org\/10.3390\/ijms22010411","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,1,2]]}}}